Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China"

被引：0
|
作者：
Guan, Haijing [1 ]
Sheng, Yanan [2 ]
Guo, Wanjie [3 ]
Han, Sheng [3 ]
Shi, Luwen [1 ]
机构：
[1] Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China
[2] Peking Univ, China Ctr Hlth Econ Res, Beijing, Peoples R China
[3] Peking Univ, Int Res Ctr Med Adm, Beijing, Peoples R China
来源：
ADVANCES IN THERAPY | 2020年 / 37卷 / 02期
关键词：
Alectinib; ALK; China; Cost-Effectiveness; NSCLC; CRIZOTINIB;
D O I：
10.1007/s12325-019-01202-2
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：971 / 972
页数：2
相关论文
共 50 条
  • [1] Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China”
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    Advances in Therapy, 2020, 37 : 971 - 972
  • [2] Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
    Mu, Lifeng
    Zhou, Benhong
    ADVANCES IN THERAPY, 2020, 37 (02) : 968 - 970
  • [3] Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
    Lifeng Mu
    Benhong Zhou
    Advances in Therapy, 2020, 37 : 968 - 970
  • [4] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    Advances in Therapy, 2019, 36 : 1114 - 1125
  • [5] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    ADVANCES IN THERAPY, 2019, 36 (05) : 1114 - 1125
  • [6] COST-EFFECTIVENESS OF CERITINIB IN PREVIOUSLY UNTREATED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN THE UNITED KINGDOM
    Xie, J.
    Knoll, S.
    Slowley, A.
    Bensimon, A.
    Vieira, J.
    Chilcott, J.
    Paisley, S.
    Zhou, Z.
    VALUE IN HEALTH, 2018, 21 : S29 - S29
  • [7] Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong
    Loong, H. H.
    Wong, C. K. H.
    Leung, L. K. S.
    Chan, C. P. K.
    Chang, A.
    Gibbs, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer
    Nishi, Koichi
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Guler, B.
    Orfanos, P.
    VALUE IN HEALTH, 2018, 21 : S40 - S40
  • [10] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
    Peters, Solange
    Camidge, D. Ross
    Shaw, Alice T.
    Gadgeel, Shirish
    Ahn, Jin S.
    Kim, Dong-Wan
    Ou, Sai-Hong I.
    Perol, Maurice
    Dziadziuszko, Rafal
    Rosell, Rafael
    Zeaiter, Ali
    Mitry, Emmanuel
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Mok, Tony
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 829 - 838
12345